Recent advances in understanding and managing leiomyosarcomas

Florence Duffaud, Isabelle Ray-Coquard, Sébastien Salas, Patricia Pautier

    Research output: Contribution to journalArticlepeer-review

    22 Citations (Scopus)

    Abstract

    Leiomyosarcomas are malignant mesenchymal tumours that derive from the smooth muscle lineage. They are studied and frequently treated as if they are the same as other soft tissue sarcomas. Recent developments suggest that a different approach may be more appropriate. Their underlying genetic mechanisms remain unclear, and complex. Unbalanced karyotypic defects are the only shared features observed across different leiomyosarcoma subtypes. Unlike other soft tissue sarcomas, leiomyosarcomas are particularly sensitive to the combination of gemcitabine and docetaxel. Furthermore, treatment with trabectedin has shown a good efficacy in leiomyosarcomas, mainly in the form of chronic disease stabilisation.

    Original languageEnglish
    Article number55
    JournalF1000Prime Reports
    Volume7
    DOIs
    Publication statusPublished - 12 May 2015

    Cite this